Literature DB >> 24903438

Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression.

T Kawai1, D H Sachs, B Sprangers, T R Spitzer, S L Saidman, E Zorn, N Tolkoff-Rubin, F Preffer, K Crisalli, B Gao, W Wong, H Morris, S A LoCascio, P Sayre, B Shonts, W W Williams, R-N Smith, R B Colvin, M Sykes, A B Cosimi.   

Abstract

We report here the long-term results of HLA-mismatched kidney transplantation without maintenance immunosuppression (IS) in 10 subjects following combined kidney and bone marrow transplantation. All subjects were treated with nonmyeloablative conditioning and an 8- to 14-month course of calcineurin inhibitor with or without rituximab. All 10 subjects developed transient chimerism, and in seven of these, IS was successfully discontinued for 4 or more years. Currently, four subjects remain IS free for periods of 4.5-11.4 years, while three required reinstitution of IS after 5-8 years due to recurrence of original disease or chronic antibody-mediated rejection. Of the 10 renal allografts, three failed due to thrombotic microangiopathy or rejection. When compared with 21 immunologically similar living donor kidney recipients treated with conventional IS, the long-term IS-free survivors developed significantly fewer posttransplant complications. Although most recipients treated with none or two doses of rituximab developed donor-specific antibody (DSA), no DSA was detected in recipients treated with four doses of rituximab. Although further revisions of the current conditioning regimen are planned in order to improve consistency of the results, this study shows that long-term stable kidney allograft survival without maintenance IS can be achieved following transient mixed chimerism induction. © Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Chimerism; immunobiology; kidney transplantation; living donors; tolerance

Mesh:

Substances:

Year:  2014        PMID: 24903438      PMCID: PMC4228952          DOI: 10.1111/ajt.12731

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  38 in total

Review 1.  Engraftment syndrome following hematopoietic stem cell transplantation.

Authors:  T R Spitzer
Journal:  Bone Marrow Transplant       Date:  2001-05       Impact factor: 5.483

Review 2.  Mixed chimerism.

Authors:  M Sykes; D H Sachs
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-05-29       Impact factor: 6.237

Review 3.  Mixed chimerism and transplant tolerance.

Authors:  M Sykes
Journal:  Immunity       Date:  2001-04       Impact factor: 31.745

4.  Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants.

Authors:  J D Scandling; S Busque; S Dejbakhsh-Jones; C Benike; M Sarwal; M T Millan; J A Shizuru; R Lowsky; E G Engleman; S Strober
Journal:  Am J Transplant       Date:  2012-03-08       Impact factor: 8.086

5.  Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys.

Authors:  Tatsuo Kawai; A Benedict Cosimi; Siew Lin Wee; Stuart Houser; David Andrews; Hiroshi Sogawa; Joanne Phelan; Svetlan Boskovic; Ognjenka Nadazdin; Gregory Abrahamian; Robert B Colvin; David H Sach; Joren C Madsen
Journal:  Transplantation       Date:  2002-06-15       Impact factor: 4.939

6.  CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates.

Authors:  Tatsuo Kawai; Hiroshi Sogawa; Svetlan Boskovic; Gregory Abrahamian; Rex-Neal Smith; Siew-Lin Wee; David Andrews; Ognjenka Nadazdin; Ichiro Koyama; Megan Sykes; Henry J Winn; Robert B Colvin; David H Sachs; A Benedict Cosimi
Journal:  Am J Transplant       Date:  2004-09       Impact factor: 8.086

7.  On the immunocompetence of H-2 incompatible irradiation bone marrow chimeras.

Authors:  R M Zinkernagel; A Althage; G Callahan; R M Welsh
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

Review 8.  The metabolic effects of cyclosporin and tacrolimus.

Authors:  P Marchetti; R Navalesi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

9.  Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance.

Authors:  T Kawai; A Poncelet; D H Sachs; S Mauiyyedi; S Boskovic; S L Wee; D S Ko; A Bartholomew; M Kimikawa; H Z Hong; G Abrahamian; R B Colvin; A B Cosimi
Journal:  Transplantation       Date:  1999-12-15       Impact factor: 4.939

10.  Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen.

Authors:  Y Sharabi; D H Sachs
Journal:  J Exp Med       Date:  1989-02-01       Impact factor: 14.307

View more
  109 in total

Review 1.  Why some organ allografts are tolerated better than others: new insights for an old question.

Authors:  Travis D Hull; Gilles Benichou; Joren C Madsen
Journal:  Curr Opin Organ Transplant       Date:  2019-02       Impact factor: 2.640

2.  Facilitating cells: Translation of hematopoietic chimerism to achieve clinical tolerance.

Authors:  Suzanne T Ildstad; Joseph Leventhal; Yujie Wen; Esma Yolcu
Journal:  Chimerism       Date:  2016-01-08

Review 3.  Mesenchymal stromal cells in renal transplantation: opportunities and challenges.

Authors:  Federica Casiraghi; Norberto Perico; Monica Cortinovis; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2016-02-08       Impact factor: 28.314

4.  Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement.

Authors:  Stephen T Bartlett; James F Markmann; Paul Johnson; Olle Korsgren; Bernhard J Hering; David Scharp; Thomas W H Kay; Jonathan Bromberg; Jon S Odorico; Gordon C Weir; Nancy Bridges; Raja Kandaswamy; Peter Stock; Peter Friend; Mitsukazu Gotoh; David K C Cooper; Chung-Gyu Park; Phillip OʼConnell; Cherie Stabler; Shinichi Matsumoto; Barbara Ludwig; Pratik Choudhary; Boris Kovatchev; Michael R Rickels; Megan Sykes; Kathryn Wood; Kristy Kraemer; Albert Hwa; Edward Stanley; Camillo Ricordi; Mark Zimmerman; Julia Greenstein; Eduard Montanya; Timo Otonkoski
Journal:  Transplantation       Date:  2016-02       Impact factor: 4.939

5.  Long-term Nonhuman Primate Renal Allograft Survival Without Ongoing Immunosuppression in Recipients of Delayed Donor Bone Marrow Transplantation.

Authors:  Kiyohiko Hotta; Tetsu Oura; Abbas Dehnadi; Svjetlan Boskovic; Masatoshi Matsunami; Ivy Rosales; Rex N Smith; Robert B Colvin; A Benedict Cosimi; Tatsuo Kawai
Journal:  Transplantation       Date:  2018-04       Impact factor: 4.939

Review 6.  Myeloid-Derived Suppressor Cells and Their Potential Application in Transplantation.

Authors:  Joseph R Scalea; Young Suk Lee; Eduardo Davila; Jonathan S Bromberg
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

Review 7.  Cell therapy for immunosuppression after kidney transplantation.

Authors:  Christian Morath; Anita Schmitt; Martin Zeier; Michael Schmitt; Flavius Sandra-Petrescu; Gerhard Opelz; Peter Terness; Matthias Schaier; Christian Kleist
Journal:  Langenbecks Arch Surg       Date:  2015-06-17       Impact factor: 3.445

Review 8.  Lost in translation? Microchimersim detection in experimental and clinical transplantation.

Authors:  Jhade D Woodall; Mehmet C Uluer; Matthew T Chrencik; Arthur J Nam; Stephen T Bartlett; Rolf N Barth
Journal:  Chimerism       Date:  2015-10-02

Review 9.  Immune monitoring as prerequisite for transplantation tolerance trials.

Authors:  K Behnam Sani; B Sawitzki
Journal:  Clin Exp Immunol       Date:  2017-06-23       Impact factor: 4.330

10.  Incomplete clonal deletion as prerequisite for tissue-specific minor antigen tolerization.

Authors:  Nina Pilat; Benedikt Mahr; Lukas Unger; Karin Hock; Christoph Schwarz; Andreas M Farkas; Ulrike Baranyi; Fritz Wrba; Thomas Wekerle
Journal:  JCI Insight       Date:  2016-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.